American Oriental Bioengineering

AOBI

Biotechnology · Healthcare

Price

$0.01

+0.00 (+0.00%)

Market Cap

$949

Winston Score

Winston is worried

Weak fundamentals across most pillars.

Data as of Aug 23, 2026 · filings through Sep 30, 2013

How the score breaks down

Quality

Weak

Growth

Weak

Cash Flow

Weak

Stability

Mixed

Valuation

Data not available

Track this stock — start free trial

Share count falling — buybacks

−6.9% over 4y

The company has reduced its share count over this period, returning value to shareholders through buybacks.

Diluted shares outstanding: 82K (2008) → 76K (2012)

Winston Score History

The full picture

American Oriental Bioengineering is a Chinese pharmaceutical and bioengineering company that makes medicines derived from natural and plant-based ingredients. Its products include traditional Chinese medicine (TCM) treatments and modern pharmaceutical drugs sold mainly to hospitals, clinics, and pharmacies across China. The company operates in the large and growing Chinese healthcare market, where demand for both traditional and modern medicines is significant.

The company earns money by selling its pharmaceutical products directly to distributors and healthcare providers in China. It is a small company with a market cap near zero, which signals serious financial stress — its operating margin is deeply negative, meaning it spends far more than it earns. The biggest risk facing the business is its ongoing inability to generate profits, and without a clear path to positive cash flow or a strong competitive advantage over larger Chinese pharmaceutical rivals, the company faces real questions about its long-term survival.

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

-39.2% YoY

YoY Growth Rate

Revenue declining

EPS Growth

-213.6% YoY

YoY Growth Rate

Earnings declining

R&D Spend

$6M/ year

↓ Declining (-51% vs prior year)

4.3% of revenue

Below sector average (18%)

R&D spend declining — could signal cost-cutting or efficiency

Insider Activity

22.9%ownership

→ Flat

Insider ownership roughly steady over the past year

Cash Runway

~0 months

$4M cash & investments

Quarterly Free Cash Flow

↓ Burn rate worsening

Short runway — potential dilution ahead through share issuance

Cash watch

American Oriental Bioengineering has less than a year of cash at its current burn rate. Growth investors should watch for potential share dilution from future fundraising — that directly reduces your ownership.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Profit per sale

Gross Margin

17.3%

Thin — 17.3% gross margin

Profit after running costs

Operating Margin

-105.8%

Losing money on operations — -105.8%

Return on the money invested

ROCE

-20.8%

Weak — -20.8% return on capital

Negative ROIC means the business is losing money on every dollar invested in it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales growth

Sales YoY

-10.2%

Shrinking sales (-10.2% YoY)

Profit growth

EPS YoY

N/A

Data not available

How steady the profit is

EPS Consistency

3/8 quarters

Earnings rarely grow — volatile business

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Profit that turns into cash

Cash Conversion

N/A

Data not available

Spare cash per sale

FCF Margin

-49.1%

Burning cash (-49.1%)

Free cash flow is negative. They are burning cash, not generating it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

What it owes vs what it owns

Debt / Equity

0.33

Conservative — low debt load (0.33)

Covers its interest

Interest Cover

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

Price vs profit

P/E Ratio (TTM)

N/M

Negative earnings — P/E not meaningful

Cheaper or dearer next year

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial